FDA Approves Once-Weekly Awiqli for Pediatric Diabetes

The regulatory agency authorized the long-acting insulin for children aged 10 and older with type 2 diabetes.

Updated on Oct. 23, 2026 in Diabetes

FDA Approves Once-Weekly Awiqli for Pediatric Diabetes

Live Poll

Would you prefer a once-weekly insulin injection over daily insulin for managing your child's diabetes?

The FDA has granted approval for Awiqli, a long-acting insulin analog, to treat type 2 diabetes in pediatric patients aged 10 years and older. The medication is intended to be used as an adjunct to diet and exercise to help manage blood glucose levels.

Why it matters

Type 2 diabetes mellitus often results in chronically high blood glucose levels when the body fails to produce or utilize insulin effectively. This approval provides a new treatment option for younger patients through a once-weekly subcutaneous injection.

The clinical study supporting this approval involved 18 pediatric patients and relied on pharmacometric modeling to compare blood levels against adult data. Awiqli is now approved for use in patients starting at 10 years of age.

The players

FDA

The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human drugs and biological products in the United States.

Awiqli

Awiqli is a long-acting insulin analog developed to help manage blood glucose levels through once-weekly administration.

The details

Administered via a once-weekly subcutaneous injection, Awiqli is expected to lower blood glucose in pediatric patients in a manner similar to its effect in adults. Common adverse reactions include hypoglycemia, weight gain, and allergic reactions, with labeling including specific warnings for medication errors and accidental overdose.

October 23, 2026: The FDA approved Awiqli for pediatric patients.

Health Landscape

This approval marks a milestone in pediatric diabetes care by utilizing clinical data and pharmacometric modeling to validate treatments previously cleared only for adults. It follows the FDA's pediatric research requirements for drug approval which ensure therapies are adapted for younger patients.

Pediatric patients aged 10 and older may now benefit from a less frequent, once-weekly insulin regimen compared to daily injections. Families should discuss the potential for side effects, including hypoglycemia and weight gain, with their healthcare provider.

The takeaway

This once-weekly treatment option may simplify insulin management for children living with type 2 diabetes. Parents and caregivers should remain diligent about monitoring for potential hypoglycemia and strictly follow dosage instructions to prevent accidental overdose.